Korean J Gastroenterol.  2023 May;81(5):203-208. 10.4166/kjg.2023.044.

Approach to the Diagnosis and Management of Gallstones

• Chung KH

• KMID: 2542786
• DOI: http://doi.org/10.4166/kjg.2023.044

Abstract

Gallstones are relatively common in the general population, and the clinical presentation is asymptomatic in most patients or has a benign course, such as biliary colic or vague gastrointestinal symptoms. On the other hand, it sometimes causes life-threatening complications, such as cholecystitis and pancreatitis. Asymptomatic gallstones do not require specific treatment, but a cholecystectomy may be necessary if the patient has a high risk of complications or gallbladder cancer. Abdominal ultrasonography is the most useful diagnostic tool for gallstones, which shows high sensitivity and specificity. In addition, endoscopic ultrasonography may be helpful when typical symptoms of gallstones are present, but gallstones are not identified with abdominal ultrasonography. Abdominal CT, MRCP, or ERCP help identify complications or other accompanying diseases caused by gallstones. Oral bile acid dissolution therapy can be attempted by administering ursodeoxycholic acid and chenodeoxycholic acid if gallstones are confirmed, but the related symptoms are mild or atypical, and the patient is unable/unwilling to undergo a cholecystectomy. A high success rate can be achieved when the treatment candidate is appropriately selected. The disadvantages of oral bile acid dissolution therapy are that there are few appropriate candidates, long-term treatment is required, and the gallstone frequently recurs when the treatment is discontinued.

Keyword

Gallstones; Disease management; Diagnosis; Symptom assessment

Reference

1. Portincasa P, Moschetta A, Palasciano G. 2006; Cholesterol gallstone disease. Lancet. 368:230–239. DOI: 10.1016/S0140-6736(06)69044-2. PMID: 16844493.

2. Unalp-Arida A, Ruhl CE. Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the US. Hepatology. 2023; Jan. 13. doi: 10.1097/HEP.0000000000000264. DOI: 10.1097/HEP.0000000000000264. PMID: 36631004.

3. Aerts R, Penninckx F. 2003; The burden of gallstone disease in Europe. Aliment Pharmacol Ther. 18 Suppl 3:49–53. DOI: 10.1046/j.0953-0673.2003.01721.x. PMID: 14531741.

4. Song ST, Shi J, Wang XH, et al. 2020; Prevalence and risk factors for gallstone disease: A population-based cross-sectional study. J Dig Dis. 21:237–245. DOI: 10.1111/1751-2980.12857. PMID: 32166900.

5. Song Y, Ma Y, Xie FC, et al. 2022; Age, gender, geographic and clinical differences for gallstones in China: a nationwide study. Ann Transl Med. 10:735. DOI: 10.21037/atm-21-6186. PMID: 35957733. PMCID: PMC9358507.

6. Nomura H, Kashiwagi S, Hayashi J, et al. 1988; Prevalence of gallstone disease in a general population of Okinawa, Japan. Am J Epidemiol. 128:598–605. DOI: 10.1093/oxfordjournals.aje.a115007. PMID: 3046339.

7. Chung YJ, Park YD, Lee HC, et al. 2007; Prevalence and risk factors of gallstones in a general health screened population. Korean J Med. 72:480–490.

8. Huang D, Lee J, Song N, Cho S, Choe S, Shin A. 2020; Gallstones, cholecystectomy and the risk of hepatobiliary and pancreatic cancer: a nationwide population-based cohort study in Korea. J Cancer Prev. 25:164–172. DOI: 10.15430/JCP.2020.25.3.164. PMID: 33033710. PMCID: PMC7523037.

9. Diehl AK, Sugarek NJ, Todd KH. 1990; Clinical evaluation for gallstone disease: usefulness of symptoms and signs in diagnosis. Am J Med. 89:29–33. DOI: 10.1016/0002-9343(90)90094-T. PMID: 2368790.

10. Festi D, Sottili S, Colecchia A, et al. 1999; Clinical manifestations of gallstone disease: evidence from the multicenter Italian study on cholelithiasis (MICOL). Hepatology. 30:839–846. DOI: 10.1002/hep.510300401. PMID: 10498631.

11. Halldestam I, Enell EL, Kullman E, Borch K. 2004; Development of symptoms and complications in individuals with asymptomatic gallstones. Br J Surg. 91:734–738. DOI: 10.1002/bjs.4547. PMID: 15164444.

12. Attili AF, De Santis A, Capri R, Repice AM, Maselli S. 1995; The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology. 21:655–660. DOI: 10.1002/hep.1840210309. PMID: 7875663.

13. Friedman GD. 1993; Natural history of asymptomatic and symptomatic gallstones. Am J Surg. 165:399–404. DOI: 10.1016/S0002-9610(05)80930-4. PMID: 8480871.

14. Friedman GD, Raviola CA, Fireman B. 1989; Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol. 42:127–136. DOI: 10.1016/0895-4356(89)90086-3. PMID: 2918322.

15. Gracie WA, Ransohoff DF. 1982; The natural history of silent gallstones: the innocent gallstone is not a myth. N Engl J Med. 307:798–800. DOI: 10.1056/NEJM198209233071305. PMID: 7110244.

16. Festi D, Reggiani ML, Attili AF, et al. 2010; Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol. 25:719–724. DOI: 10.1111/j.1440-1746.2009.06146.x. PMID: 20492328.

17. Shabanzadeh DM, Sørensen LT, Jørgensen T. 2016; A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 150:156–167.e1. DOI: 10.1053/j.gastro.2015.09.002. PMID: 26375367.

18. Collins C, Maguire D, Ireland A, Fitzgerald E, O'Sullivan GC. 2004; A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg. 239:28–33. DOI: 10.1097/01.sla.0000103069.00170.9c. PMID: 14685097. PMCID: PMC1356189.

19. Shea JA, Berlin JA, Escarce JJ, et al. 1994; Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med. 154:2573–2581. DOI: 10.1001/archinte.1994.00420220069008. PMID: 7979854.

20. Garra BS, Davros WJ, Lack EE, Horii SC, Silverman PM, Zeman RK. 1990; Visibility of gallstone fragments at US and fluoroscopy: implications for monitoring gallstone lithotripsy. Radiology. 174:343–347. DOI: 10.1148/radiology.174.2.2404312. PMID: 2404312.

21. Neoptolemos JP, Hall AW, Finlay DF, Berry JM, Carr-Locke DL, Fossard DP. 1984; The urgent diagnosis of gallstones in acute pancreatitis: a prospective study of three methods. Br J Surg. 71:230–233. DOI: 10.1002/bjs.1800710324. PMID: 6141833.

22. Einstein DM, Lapin SA, Ralls PW, Halls JM. 1984; The insensitivity of sonography in the detection of choledocholithiasis. AJR Am J Roentgenol. 142:725–728. DOI: 10.2214/ajr.142.4.725. PMID: 6608231.

23. Barakos JA, Ralls PW, Lapin SA, et al. 1987; Cholelithiasis: evaluation with CT. Radiology. 162:415–418. DOI: 10.1148/radiology.162.2.3797654. PMID: 3797654.

24. Buxbaum JL, Abbas Fehmi SM, Sultan S, et al. ASGE Standards of Practice Committee. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019; 89:1075–1105.e15. DOI: 10.1016/j.gie.2018.10.001. PMID: 30979521. PMCID: PMC8594622.

25. Dahan P, Andant C, Lévy P, et al. 1996; Prospective evaluation of endoscopic ultrasonography and microscopic examination of duodenal bile in the diagnosis of cholecystolithiasis in 45 patients with normal conventional ultrasonography. Gut. 38:277–281. DOI: 10.1136/gut.38.2.277. PMID: 8801211. PMCID: PMC1383037.

26. Liu CL, Lo CM, Chan JK, Poon RT, Fan ST. 2000; EUS for detection of occult cholelithiasis in patients with idiopathic pancreatitis. Gastrointest Endosc. 51:28–32. DOI: 10.1016/S0016-5107(00)70382-8. PMID: 10625791.

27. Dill JE, Hill S, Callis J, et al. 1995; Combined endoscopic ultrasound and stimulated biliary drainage in cholecystitis and microlithiasis--diagnoses and outcomes. Endoscopy. 27:424–427. DOI: 10.1055/s-2007-1005734. PMID: 8549438.

28. Trevino F, Carter O. 1984; Gallstone size and the risk of gallbladder cancer. JAMA. 251:3080–3081. DOI: 10.1001/jama.1984.03340470016009. PMID: 6726976.

29. Lowenfels AB, Walker AM, Althaus DP, Townsend G, Domellöf L. 1989; Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol. 18:50–54. DOI: 10.1093/ije/18.1.50. PMID: 2722383.

30. Shiffman ML, Sugerman HJ, Kellum JM, Brewer WH, Moore EW. 1991; Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol. 86:1000–1005.

31. Wattchow DA, Hall JC, Whiting MJ, Bradley B, Iannos J, Watts JM. 1983; Prevalence and treatment of gall stones after gastric bypass surgery for morbid obesity. Br Med J (Clin Res Ed). 286:763. DOI: 10.1136/bmj.286.6367.763. PMID: 6402238. PMCID: PMC1547033.

32. Reiss R, Nudelman I, Gutman C, Deutsch AA. 1990; Changing trends in surgery for acute cholecystitis. World J Surg. 14:567–570. discussion 570–571. DOI: 10.1007/BF01658790. PMID: 2238655.

33. Sugerman HJ, Brewer WH, Shiffman ML, et al. 1995; A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg. 169:91–96. discussion 96–97. DOI: 10.1016/S0002-9610(99)80115-9. PMID: 7818005.

34. Venneman NG, Besselink MG, Keulemans YC, et al. 2006; Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology. 43:1276–1283. DOI: 10.1002/hep.21182. PMID: 16729326.

35. Lee SH, Jang DK, Yoo MW, et al. Efficacy and Safety of DWJ1319 in the Prevention of Gallstone Formation after Gastrectomy in Patient with Gastric Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled Study (PEGASUS-D) Group. Efficacy and safety of ursodeoxycholic acid for the prevention of gallstone formation after gastrectomy in patients with gastric cancer: The PEGASUS-D randomized clinical trial. JAMA Surg. 2020; 155:703–711. DOI: 10.1001/jamasurg.2020.1501. PMID: 32584935. PMCID: PMC7301302.

36. Petroni ML, Jazrawi RP, Pazzi P, et al. 2001; Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group. Aliment Pharmacol Ther. 15:123–128. DOI: 10.1046/j.1365-2036.2001.00853.x. PMID: 11136285.

37. Jazrawi RP, Pigozzi MG, Galatola G, Lanzini A, Northfield TC. 1992; Optimum bile acid treatment for rapid gall stone dissolution. Gut. 33:381–386. DOI: 10.1136/gut.33.3.381. PMID: 1568660. PMCID: PMC1373833.

38. May GR, Sutherland LR, Shaffer EA. 1993; Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. Aliment Pharmacol Ther. 7:139–148. DOI: 10.1111/j.1365-2036.1993.tb00082.x. PMID: 8485266.

39. Hyun JJ, Lee HS, Kim CD, et al. 2015; Efficacy of magnesium trihydrate of ursodeoxycholic acid and chenodeoxycholic acid for gallstone dissolution: a prospective multicenter trial. Gut Liver. 9:547–555. DOI: 10.5009/gnl15015. PMID: 26087862. PMCID: PMC4478000.

40. Maton PN, Iser JH, Reuben A, Saxton HM, Murphy GM, Dowling RH. 1982; Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence. Medicine (Baltimore). 61:86–97. DOI: 10.1097/00005792-198203000-00003. PMID: 7062856.

41. Petroni ML, Jazrawi RP, Pazzi P, et al. 2000; Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol. 12:695–700. DOI: 10.1097/00042737-200012060-00020. PMID: 10912491.

42. Lanzini A, Jazrawi RP, Kupfer RM, Maudgal DP, Joseph AE, Northfield TC. 1986; Gallstone recurrence after medical dissolution. An overestimated threat? J Hepatol. 3:241–246. DOI: 10.1016/S0168-8278(86)80033-2. PMID: 3540098.

43. Villanova N, Bazzoli F, Taroni F, et al. 1989; Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment. Gastroenterology. 97:726–731. DOI: 10.1016/0016-5085(89)90644-6. PMID: 2753332.